Celiac Science
Argenx's $2.2 Billion Acquisition: What a Vitiligo Deal Means for Celiac Patients
Argenx acquires Forte for $2.2B and its phase 2 vitiligo drug. Here's why this autoimmune deal matters to celiac patients and families.
Celiac Science
$15 Million Invested in Cell Therapy That Could Transform How Celiac Disease Is Treated
A Philadelphia biotech raised $15.1M to develop cell-based therapies for autoimmune disease. Here's what that investment signals for celiac families watching the treatment pipeline.
Celiac Science
Beyond the Gluten-Free Diet: A New Era of Celiac Treatments May Be Coming
A major review outlines promising celiac disease treatments in development, from gluten-digesting enzymes to immune tolerance therapies.